Display options
Cite
Negash AA, Asrat D, Abebe W, et al. Phenotypic and Molecular Characterization of Penicillin and Macrolide-Resistant . Infect Drug Resist. 2021;14:1765-1772doi: 10.2147/IDR.S309876.
Negash, A. A., Asrat, D., Abebe, W., Aseffa, A., & Vaneechoutte, M. (2021). Phenotypic and Molecular Characterization of Penicillin and Macrolide-Resistant . Infection and drug resistance, 141765-1772. https://doi.org/10.2147/IDR.S309876
Negash, Abel Abera, et al. "Phenotypic and Molecular Characterization of Penicillin and Macrolide-Resistant ." Infection and drug resistance vol. 14 (2021): 1765-1772. doi: https://doi.org/10.2147/IDR.S309876
Negash AA, Asrat D, Abebe W, Aseffa A, Vaneechoutte M. Phenotypic and Molecular Characterization of Penicillin and Macrolide-Resistant . Infect Drug Resist. 2021 May 12;14:1765-1772. doi: 10.2147/IDR.S309876. eCollection 2021. PMID: 34012275; PMCID: PMC8126871.
Copy Download .nbib Format: NLM
Share it on

Infect Drug Resist. 2021 May 12;14:1765-1772. doi: 10.2147/IDR.S309876. eCollection 2021.

Phenotypic and Molecular Characterization of Penicillin and Macrolide-Resistant .

Infection and drug resistance

Abel Abera Negash, Daniel Asrat, Workeabeba Abebe, Abraham Aseffa, Mario Vaneechoutte

Affiliations

  1. Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
  2. Department of Microbiology, Immunology and Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
  3. Department of Pediatrics and Child Health, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
  4. Laboratory Bacteriology Research, Department of Diagnostic Sciences, Faculty of Medicine & Health Sciences, Ghent University, Ghent, Belgium.

PMID: 34012275 PMCID: PMC8126871 DOI: 10.2147/IDR.S309876

Abstract

BACKGROUND: In several countries, introduction of the pneumococcal conjugate vaccine (PCV) has led to a decline in antimicrobial-resistant pneumococcal disease but has also resulted in a concomitant increase in antimicrobial-resistant, non-vaccine serotypes of

METHODS: Susceptibility to penicillin and erythromycin of 119 pneumococcal isolates collected from pediatric patients aged 0-15 years in Addis Ababa, Ethiopia, was tested using disc diffusion, and minimum inhibitory concentration (MIC) was also determined by Etest. Pneumococcal serotypes were determined by sequencing the

RESULTS: Among the 119 isolates, 2.5% (3/119) were resistant to penicillin, while 58% (69/119) were intermediate. Resistance to erythromycin was observed in 33.6% (40/119) of the isolates with the highest level of resistance among isolates from middle ear discharge, i.e., 53.3% (8/15). Half (19/40) of the erythromycin resistant isolates were serotype 19A and among serotype 19A isolates, the majority i.e., 54.3% (19/35) were resistant to erythromycin. The most common macrolide resistance determinant was

CONCLUSION: Five years after introduction of PCV10 in Ethiopia, we observed that the prevalence of penicillin-resistant

© 2021 Negash et al.

Keywords: PCV10; Streptococcus pneumoniae; efflux pump; erythromycin; mef(E); penicillin; serotype 19A

Conflict of interest statement

Dr Abel Abera Negash reported grants from VLIR-UOS during the conduct of the study. The authors reported no other potential conflicts of interest for this work.

References

  1. Paediatr Int Child Health. 2018 Feb;38(1):7-15 - PubMed
  2. J Infect Dev Ctries. 2021 Jan 31;15(1):113-122 - PubMed
  3. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:39-47 - PubMed
  4. Lancet Glob Health. 2018 Jul;6(7):e744-e757 - PubMed
  5. Clin Microbiol Rev. 1990 Apr;3(2):171-96 - PubMed
  6. PLoS Med. 2010 Dec 14;7(12):e1000377 - PubMed
  7. Clin Infect Dis. 2006 Jan 15;42(2):234-7 - PubMed
  8. Open Forum Infect Dis. 2019 May 31;6(6):ofz259 - PubMed
  9. Antimicrob Agents Chemother. 1996 Nov;40(11):2562-6 - PubMed
  10. J Infect Dis. 2015 Apr 1;211(7):1144-53 - PubMed
  11. PLoS One. 2018 Nov 29;13(11):e0208211 - PubMed
  12. Am J Clin Pathol. 1966 Apr;45(4):493-6 - PubMed
  13. J Clin Microbiol. 1993 Aug;31(8):2097-100 - PubMed
  14. Front Cell Infect Microbiol. 2016 Sep 21;6:98 - PubMed
  15. BMC Ear Nose Throat Disord. 2018 May 24;18:8 - PubMed
  16. Int J Pediatr Otorhinolaryngol. 2019 Nov;126:109638 - PubMed
  17. Clin Microbiol Infect. 2010 May;16(5):402-10 - PubMed
  18. Clin Infect Dis. 2020 Feb 14;70(5):814-826 - PubMed
  19. J Clin Microbiol. 2004 Aug;42(8):3570-4 - PubMed
  20. Open Forum Infect Dis. 2019 Jan 23;6(3):ofz029 - PubMed
  21. Antimicrob Agents Chemother. 1997 Oct;41(10):2251-5 - PubMed
  22. Front Microbiol. 2019 Apr 24;10:868 - PubMed
  23. Antimicrob Agents Chemother. 1999 Dec;43(12):2823-30 - PubMed
  24. Pneumonia (Nathan). 2016 Jul 7;8:10 - PubMed
  25. Pneumonia (Nathan). 2017 May 25;9:8 - PubMed
  26. Expert Rev Vaccines. 2019 Oct;18(10):1069-1089 - PubMed
  27. Pediatr Neonatol. 2013 Oct;54(5):315-21 - PubMed
  28. Front Microbiol. 2019 Mar 14;10:486 - PubMed
  29. Trop Med Int Health. 1999 Jun;4(6):421-7 - PubMed
  30. J Pediatric Infect Dis Soc. 2016 Jun;5(2):222-6 - PubMed
  31. J Clin Microbiol. 2000 Oct;38(10):3870-1 - PubMed
  32. BMC Res Notes. 2019 May 7;12(1):253 - PubMed
  33. N Engl J Med. 2014 Nov 13;371(20):1889-99 - PubMed
  34. Antimicrob Agents Chemother. 2013 Nov;57(11):5415-22 - PubMed
  35. Lancet Glob Health. 2017 Dec;5(12):e1176-e1177 - PubMed

Publication Types